Monthly Archives: February 2016

Patented or generic? Time for the CMA to speak on pharmaceutical ‘pay-for-delay’ arrangements

Encouraging the development of innovative medicines and at the same time maintaining the steady flow of existing ones so that patients can access treatment at the point of need is an ongoing challenge for the pharmaceutical industry: in this context … Continue reading

Posted in Uncategorized | Leave a comment